Microport Scientific Corp. · HKEX:853
Microport Scientific — H1 2022 Earnings Presentation
27 slides from Microport Scientific's earnings presentation, Sep 1, 2022
Slide 1: MicroPort Scientific Corporation 2022 Interim Results
MicroPort Scientific Corporation 2022 Interim Results
Slide 2: Disclaimer
2022 Interim Results Disclaimer September 2022 This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no
Slide 3: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 4: Outstanding performance amid COVID across all segments 1H2022 Highlights
2022 Interim Results Outstanding performance amid COVID across all segments September 2022 1H2022 Highlights Cardiovascular • Int’l revenue ↑28% YOY Revenue • EMEA ↑63%, South America ↑49%, India JV2 ↑31% Total-cardio solutions • Balloon revenue ↑31% YOY $405.0mn 10.1%YOY CRM • Int’l revenue ↑8% YOY
Slide 5: Global business developed rapidly through great strategic layout
2022 Interim Results Global business developed rapidly through great strategic layout September 2022 EMEA Americas Global Strategic Triangle ↑ 14% YOY Revenue growth ↑ 10% YOY Revenue growth South Korea Asia1 • Neuro: NUMEN® approved & commercialized • Heart valve: VitaFlow ↑ 7% YOY EU Liberty™ regi
Slide 6: Distinguished product highlights and clinical progress
2022 Interim Results Distinguished product highlights and clinical progress September 2022 14 NMPA1 newly obtained 5 FDA & 5 CE China 26 Green Path products - No.1 in industry for 7 years Non-China newly obtained • Firehawk® Pro obtained NMPA • Firehawk® & Firehawk Liberty™ received 4 new registrati
Slide 7: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 8: Cardiovascular business
2022 Interim Results Cardiovascular business September 2022 Business highlights 1H22 revenue $51mn, down 11.7% YOY due to pandemic Revenue Overview Guaranteed DES volume highly increased in 2nd-year renewal of VBP for Firebird2® & FirekingfisherTM USD: million China DES products covered 3,000+ hospi
Slide 9: Orthopedics business
2022 Interim Results Orthopedics business September 2022 Non-China business China business Revenue Breakdown by region Revenue Spine & Trauma USD: million USD: million +10% +35% EMEA 31% 15.1 99.7 Revenue growth EMEA: ↑ 32% US 3.4 42% 1H22 US: ↑ 3% 8.0 2.5 95.0 Japan 18% Others 9% 1H21 1H22 1H21 1H2
Slide 10: CRM business
2022 Interim Results CRM business September 2022 Non-China business China business Revenue Revenue USD: million +8% USD: million Top 1 102.2 98.9 One of the 6.0 5.5 Chinese player only 5 No. 1 multi-national players market share for China-made products 1H21 1H22 * 1H21 1H22 * due to enormous depreci
Slide 11: Endovascular business
2022 Interim Results Endovascular business September 2022 Business highlights Product pipeline Key Financials Product Pre-clinical Clinical Registration USD: million +27% 1H21 1H22 70.8 +18% Talos® Thoracic +15% Stent Graft NMPA approved 55.8 System 39.4 33.4 32.8 28.5 Aortics Cratos® Branched Ste
Slide 12: Neurovascular business
2022 Interim Results Neurovascular business September 2022 Successfully listed on HKEx on July 15, 2022 Product Pre-clinical Clinical Registration 2172.HK Becoming the 4th subsidiary to accomplish public listing NUMEN Silk™ 3D Electro- NMPA approved nically Detachable Coil Revenue Revenue Breakdow
Slide 13: Heart valve business
2022 Interim Results Heart valve business September 2022 Business highlights Product pipeline Key financials Gross profit margin Product Pre-clinical Clinical Registration USD: million 1H21 +9ppts • CE marking in progress +45% VitaFlow Liberty™ 1H22 +67% 63.7% VitaFlow™ III • Design fixing stage 19.
Slide 14: Surgical robot business
2022 Interim Results Surgical robot business September 2022 Business highlights Product Pre-clinical Clinical Registration • Obtained first bidding order at hospital level for Toumai® Toumai® Laparoscopic Obtained NMPA • Deployed ~30 training centers, incl. self-owned and co-developed Surgical Rob
Slide 15: Emerging business
2022 Interim Results Emerging business September 2022 Urinary, gynecological, Medical imaging digestive & respiratory • Provide innovative total solutions in endoscope and • Provide total precise interventional imaging solution disposal devices to urological, gastrointestinal, • OCT successfully com
Slide 16: Emerging business (con't)
Emerging business (con’ t) 2022 Interim Results September 2022 Business highlights Materials & intelligent manufacturing service TOP 1 Chinese 3D catheter RF ablation player with Provide world’s leading comprehensive solutions incl. 30,000+ 3D navigation cases performed upstream raw material, CD
Slide 17: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 18: Consolidated financial performance
2022 Interim Results Consolidated financial performance September 2022 Revenue Gross profit margin USD: million +10.1% 405.0 64.4% 61.2% 384.6 1H21 1H22 1H21 1H22 Operating expenses Total net loss & net loss attributable to equity shareholders USD: million USD: million Net Loss Attributable to Equit
Slide 19: Operating expenses
2022 Interim Results Operating expenses September 2022 Sales & marketing expenses Administrative expenses R&D expenses USD: million USD: million USD: million 200 46.0% 49.0% 40.0% 50.0% 160 200.0 32.9% 180 44.0% 45.0% 35.0% 140 160 39.0% 36.2% 40.0% 26.8% 30.0% 34.0% 120 140 30.4% 34.0% 150.0 35.0%
Slide 20: Net loss analysis by segment
2022 Interim Results Net loss analysis by segment September 2022 USD: million Increased R&D expenses Firehawk® large-scale clinical trials • Increased China COVID Increased JV loss & joints VBP R&D in MRI- • Accrued CB compatible interests Accrued (non-cash) products interests • Other of preferred f
Slide 21: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 22: Innovative product pipeline fueling long-term growth
2022 Interim Results Innovative product pipeline fueling long-term growth September 2022 Firesorb® Coronary Coronary Rotational Intravascular Coronary Rapamycin Firefighter™ Cardio- Anchor Balloon Bioresorbable Firehawk® Stent Graft Atherectomy Lithotripsy Drug-coated Balloon Pro/NC Pro vascular NMP
Slide 23: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 24: Appendix I - Consolidated income statement
2022 Interim Results Appendix I - Consolidated income statement September 2022 USD'000 2022 1H 2021 1H Var. Revenue 404,984 384,611 5.3% Cost of sales (157,282) (137,003) 14.8% Gross profit 247,702 247,608 0.0% Other net income 41,356 24,622 68.0% Research and development costs (186,430) (117,064) 5
Slide 25: Appendix II - Consolidated balance sheet
2022 Interim Results Appendix II - Consolidated balance sheet September 2022 USD'000 30 June 2022 31 Dec 2021 Var. Non-current assets Investment properties 7,003 7,407 -5% Other property, plant and equipment 921,380 922,874 0% Intangible assets 238,458 256,609 -7% Goodwill 280,194 290,565 -4% Equity
Slide 26: Appendix II - Consolidated balance sheet
2022 Interim Results Appendix II - Consolidated balance sheet September 2022 USD'000 30 June 2022 31 Dec 2021 Var. Non-current liablities Interest-bearing borrowings 308,720 269,637 14% Lease liabilities 137,454 168,437 -18% Deferred income 32,885 35,098 -6% Convertible bonds 668,380 660,369 1% Cont
Slide 27: Disclaimer
2022 Interim Results Disclaimer September 2022 This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no